Impact of emicizumab on mental liberation in haemophilia A patients

Prof Dr Cédric Hermans, a haematologist at Cliniques Universitaires Saint-Luc in Brussels presented data on emicizumab, a new treatment for haemophilia A. This bispecific antibody mimics the cofactor activity of coagulation FVIII and is administered subcutaneously weekly or every 2-4 weeks, ensuring stable haemostatic activity. Emicizumab offers several benefits, including improved access to prophylaxis for patients unable to perform regular intravenous infusions, better haemostatic control with lower bleeding rates, and enhanced quality of life. 

A survey of patients explored the mental liberation from haemophilia, a concept reflecting freedom from the physical and mental burdens of the disease and its treatment. Patients were asked if they experienced “haemophilia-free” days and what obstacles remained. Among over 50 respondents, 80% reported mental liberation. Those not liberated cited ongoing physical limitations or pain as primary reasons. These challenges often stem from inadequate treatments in their youth, leaving lasting effects.

This survey highlights the significant potential of emicizumab to free adult persons with haemophilia from both the physical and mental burdens of the disease. It underscores the importance of tracking “haemophilia-free mind” days as a valuable metric in evaluating patient well-being and treatment impact.